Anti-ApoA-1 IgG antibodies initially found in SLE patients were associated with a higher prevalence and incidence of CAD with a worse prognosis, independently of traditional CV risk factors observed in autoimmune and non-autoimmune settings6,12–18. Here, APOA1 is linked to systemic lupus erythematosus.